Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: a multicenter cohort study
MYC/MYCN are the most frequent oncogene amplifications in medulloblastoma (MB) and its primary biomarkers of high-risk (HR) disease. However, while many patients’ MYC(N)-amplified tumors are treatment-refractory, some achieve long-term survival. We therefore investigated clinicobiological heterogene...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 2025
|
| In: |
Neuro-Oncology
Year: 2025, Jahrgang: 27, Heft: 1, Pages: 222-236 |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/noae178 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1093/neuonc/noae178 Verlag, kostenfrei, Volltext: https://academic.oup.com/neuro-oncology/article/27/1/222/7815636?login=true 
|
| Verfasserangaben: | Edward C. Schwalbe, Janet C. Lindsey, Marina Danilenko, Rebecca M. Hill, Stephen Crosier, Sarra L. Ryan, Daniel Williamson, Jemma Castle, Debbie Hicks, Marcel Kool, Till Milde, Andrey Korshunov, Stefan M. Pfister, Simon Bailey, Steven C. Clifford |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1923068970 | ||
| 003 | DE-627 | ||
| 005 | 20250717010442.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250416s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/neuonc/noae178 |2 doi | |
| 035 | |a (DE-627)1923068970 | ||
| 035 | |a (DE-599)KXP1923068970 | ||
| 035 | |a (OCoLC)1528044664 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schwalbe, Edward C. |e VerfasserIn |0 (DE-588)1363218425 |0 (DE-627)1923070312 |4 aut | |
| 245 | 1 | 0 | |a Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes |b a multicenter cohort study |c Edward C. Schwalbe, Janet C. Lindsey, Marina Danilenko, Rebecca M. Hill, Stephen Crosier, Sarra L. Ryan, Daniel Williamson, Jemma Castle, Debbie Hicks, Marcel Kool, Till Milde, Andrey Korshunov, Stefan M. Pfister, Simon Bailey, Steven C. Clifford |
| 264 | 1 | |c January 2025 | |
| 264 | 4 | |c 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 08. Oktober 2024 | ||
| 500 | |a Gesehen am 16.04.2025 | ||
| 520 | |a MYC/MYCN are the most frequent oncogene amplifications in medulloblastoma (MB) and its primary biomarkers of high-risk (HR) disease. However, while many patients’ MYC(N)-amplified tumors are treatment-refractory, some achieve long-term survival. We therefore investigated clinicobiological heterogeneity within MYC(N)-amplified MB and determined its relevance for improved disease management.We characterized the clinical and molecular correlates of MYC- (MYC-MB; n = 64) and MYCN-amplified MBs (MYCN-MB; n = 95), drawn from >1600 diagnostic cases.Most MYC-MBs were molecular group 3 (46/58; 79% assessable) and aged ≥3 years at diagnosis (44/64 [69%]). We identified a “canonical” very high-risk (VHR) MYC-amplified group (n = 51/62; 82%) with dismal survival irrespective of treatment (11% 5-year progression-free survival [PFS]), defined by co-occurrence with ≥1 additional established risk factor(s) (subtotal surgical-resection [STR], metastatic disease, LCA pathology), and commonly group 3/4 subgroup 2 with a high proportion of amplified cells. The majority of remaining noncanonical MYC-MBs survived (i.e. non-group 3/group 3 without other risk features; 11/62 (18%); 61% 5-year PFS). MYCN survival was primarily related to molecular group; MYCN-amplified SHH MB, and group 3/4 MB with additional risk factors, respectively defined VHR and HR groups (VHR, 39% [35/89]; 20% 5-year PFS/HR, 33% [29/89]; 46% 5-year PFS). Twenty-two out of 35 assessable MYCN-amplified SHH tumors harbored TP53 mutations; 9/12 (75%) with data were germline. MYCN-amplified group 3/4 MB with no other risk factors (28%; 25/89) had 70% 5-year PFS.MYC(N)-amplified MB displays significant clinicobiological heterogeneity. Diagnostics incorporating molecular groups, subgroups, and clinical factors enable their risk assessment. VHR “canonical” MYC tumors are essentially incurable and SHH-MYCN-amplified MBs fare extremely poorly (20% survival at 5 years); both require urgent development of alternative treatment strategies. Conventional risk-adapted therapies are appropriate for more responsive groups, such as noncanonical MYC and non-SHH-MYCN MB. | ||
| 700 | 1 | |a Lindsey, Janet C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Danilenko, Marina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hill, Rebecca M. |e VerfasserIn |0 (DE-588)1269030310 |0 (DE-627)1817690205 |4 aut | |
| 700 | 1 | |a Crosier, Stephen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ryan, Sarra |e VerfasserIn |0 (DE-588)1160211388 |0 (DE-627)1023342219 |0 (DE-576)50555934X |4 aut | |
| 700 | 1 | |a Williamson, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Castle, Jemma |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hicks, Debbie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kool, Marcel |e VerfasserIn |0 (DE-588)1058669753 |0 (DE-627)797393560 |0 (DE-576)414823842 |4 aut | |
| 700 | 1 | |a Milde, Till |d 1973- |e VerfasserIn |0 (DE-588)1038311837 |0 (DE-627)75711234X |0 (DE-576)39229334X |4 aut | |
| 700 | 1 | |a Korshunov, Andrey |e VerfasserIn |0 (DE-588)1043235361 |0 (DE-627)770439365 |0 (DE-576)394592093 |4 aut | |
| 700 | 1 | |a Pfister, Stefan |d 1974- |e VerfasserIn |0 (DE-588)123850215 |0 (DE-627)706450930 |0 (DE-576)293908400 |4 aut | |
| 700 | 1 | |a Bailey, Simon |e VerfasserIn |4 aut | |
| 700 | 1 | |a Clifford, Steven C. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuro-Oncology |d Oxford : Oxford Univ. Press, 1999 |g 27(2025), 1, Seite 222-236 |h Online-Ressource |w (DE-627)357167341 |w (DE-600)2094060-9 |w (DE-576)318041839 |x 1523-5866 |7 nnas |a Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes a multicenter cohort study |
| 773 | 1 | 8 | |g volume:27 |g year:2025 |g number:1 |g pages:222-236 |g extent:15 |a Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes a multicenter cohort study |
| 856 | 4 | 0 | |u https://doi.org/10.1093/neuonc/noae178 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/neuro-oncology/article/27/1/222/7815636?login=true |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250416 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 123850215 |a Pfister, Stefan |m 123850215:Pfister, Stefan |d 910000 |d 910500 |e 910000PP123850215 |e 910500PP123850215 |k 0/910000/ |k 1/910000/910500/ |p 13 | ||
| 998 | |g 1038311837 |a Milde, Till |m 1038311837:Milde, Till |d 50000 |e 50000PM1038311837 |k 0/50000/ |p 11 | ||
| 998 | |g 1058669753 |a Kool, Marcel |m 1058669753:Kool, Marcel |d 140000 |e 140000PK1058669753 |k 0/140000/ |p 10 | ||
| 999 | |a KXP-PPN1923068970 |e 4706047781 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"language":["eng"],"note":["Gesehen am 21.07.23"],"pubHistory":["1.1999 -"],"origin":[{"publisher":"Oxford Univ. Press ; Duke University Medical Center","dateIssuedKey":"1999","publisherPlace":"Oxford ; Durham, NC","dateIssuedDisp":"1999-"}],"disp":"Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes a multicenter cohort studyNeuro-Oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"357167341","id":{"issn":["1523-5866"],"zdb":["2094060-9"],"eki":["357167341"]},"title":[{"title":"Neuro-Oncology","subtitle":"official journal of the World Federation of Neuro-Oncology","title_sort":"Neuro-Oncology"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2025","pages":"222-236","issue":"1","extent":"15","text":"27(2025), 1, Seite 222-236","volume":"27"}}],"physDesc":[{"extent":"15 S.","noteIll":"Illustrationen"}],"title":[{"title":"Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes","title_sort":"Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes","subtitle":"a multicenter cohort study"}],"recId":"1923068970","id":{"eki":["1923068970"],"doi":["10.1093/neuonc/noae178"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Edward C. Schwalbe, Janet C. Lindsey, Marina Danilenko, Rebecca M. Hill, Stephen Crosier, Sarra L. Ryan, Daniel Williamson, Jemma Castle, Debbie Hicks, Marcel Kool, Till Milde, Andrey Korshunov, Stefan M. Pfister, Simon Bailey, Steven C. Clifford"]},"origin":[{"dateIssuedDisp":"January 2025","dateIssuedKey":"2025"}],"note":["Online verfügbar: 08. Oktober 2024","Gesehen am 16.04.2025"],"language":["eng"],"person":[{"given":"Edward C.","display":"Schwalbe, Edward C.","family":"Schwalbe","role":"aut"},{"family":"Lindsey","role":"aut","display":"Lindsey, Janet C.","given":"Janet C."},{"given":"Marina","role":"aut","family":"Danilenko","display":"Danilenko, Marina"},{"display":"Hill, Rebecca M.","family":"Hill","role":"aut","given":"Rebecca M."},{"display":"Crosier, Stephen","family":"Crosier","role":"aut","given":"Stephen"},{"given":"Sarra","display":"Ryan, Sarra","role":"aut","family":"Ryan"},{"given":"Daniel","display":"Williamson, Daniel","family":"Williamson","role":"aut"},{"family":"Castle","role":"aut","display":"Castle, Jemma","given":"Jemma"},{"given":"Debbie","display":"Hicks, Debbie","role":"aut","family":"Hicks"},{"given":"Marcel","display":"Kool, Marcel","role":"aut","family":"Kool"},{"given":"Till","family":"Milde","role":"aut","display":"Milde, Till"},{"given":"Andrey","family":"Korshunov","role":"aut","display":"Korshunov, Andrey"},{"given":"Stefan","family":"Pfister","role":"aut","display":"Pfister, Stefan"},{"display":"Bailey, Simon","role":"aut","family":"Bailey","given":"Simon"},{"given":"Steven C.","display":"Clifford, Steven C.","role":"aut","family":"Clifford"}]} | ||
| SRT | |a SCHWALBEEDMOLECULARA2025 | ||